Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRANXENE vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzodiazepine; enhances GABA-A receptor activity by binding to benzodiazepine site, increasing chloride ion influx and neuronal hyperpolarization.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Anxiety disorders,Short-term relief of anxiety symptoms,Alcohol withdrawal syndrome,Adjunctive treatment for partial seizures
Mild to moderate pain,Pain accompanied by fever
7.5 mg to 15 mg orally 2 to 4 times daily; maximum dose 90 mg/day.
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Terminal elimination half-life of the active metabolite desmethyldiazepam is 30-200 hours (mean ~100 hours); parent drug clorazepate is rapidly hydrolyzed and has negligible half-life. Accumulation occurs with repeated dosing, leading to delayed peak effects and prolonged sedation.
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Hepatic via oxidative metabolism; primarily by CYP3A4 and CYP2C19 to active metabolite nordazepam, then to oxazepam and others. Also undergoes glucuronidation.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Primarily renal (80-90% as conjugated metabolites, including oxazepam and desmethyldiazepam); biliary/fecal excretion accounts for <10%.
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Clorazepate and desmethyldiazepam: 95-98% bound to albumin.
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
Clorazepate: 0.2-0.3 L/kg. Desmethyldiazepam: 0.5-1.5 L/kg (large Vd indicates extensive tissue distribution).
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Oral: nearly 100% (prodrug completely hydrolyzed in gastric acid to desmethyldiazepam). Intramuscular: erratic and incomplete (approximately 50-70% bioavailability due to variable absorption).
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
GFR 10-50 m L/min: reduce dose by 25%; GFR <10 m L/min: reduce dose by 50% and use with caution.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Children 9-12 years: 7.5 mg orally twice daily; increase to 7.5 mg three times daily if needed. Not recommended under 9 years.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
Initiate at 3.75 mg orally 1 to 2 times daily; titrate slowly to avoid sedation and falls.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for patients with inadequate alternative treatment options.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Risk of dependence and withdrawal seizures with abrupt discontinuation,CNS depressant effects may impair driving or operating machinery,Use caution in hepatic impairment,Avoid in pregnancy (risk of neonatal withdrawal and floppy infant syndrome),Potential for anterograde amnesia,Elderly patients at increased risk for adverse effects
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Hypersensitivity to clorazepate or other benzodiazepines,Acute narrow-angle glaucoma,Severe hepatic impairment,Pregnancy (especially first trimester),Breastfeeding,Concomitant use with opioids unless alternative treatments are inadequate
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
No specific food interactions. Grapefruit juice does not significantly affect metabolism. Fatty meals may delay absorption of oral clorazepate, but overall bioavailability not affected.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip/palate, when used during the first trimester. Second and third trimesters: Chronic use may lead to physical dependence and withdrawal symptoms in the neonate, including floppy infant syndrome, respiratory depression, and feeding difficulties. Late pregnancy or near delivery: Risk of neonatal sedation, hypotonia, and withdrawal.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Excreted in human milk. M/P ratio not established. Case reports indicate low milk levels (approx 4-10% of maternal weight-adjusted dose) but infant accumulation possible due to long half-life. Benefits of breastfeeding should be weighed against potential risks of sedation and poor feeding in the infant. Monitor infant for drowsiness, poor suckling, and weight loss.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
Due to increased volume of distribution and enhanced clearance, higher doses may be required during pregnancy to maintain efficacy, especially in the second and third trimesters. However, dose adjustment should be individualized and cautious because of potential fetal risks. Use the lowest effective dose for the shortest duration. Avoid high doses near term.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
TRANXENE (clorazepate) is a benzodiazepine prodrug that is decarboxylated in the stomach to the active metabolite N-desmethyldiazepam. Onset of action is relatively slow (1-2 hours) compared to diazepam. Due to its long half-life (up to 100 hours for active metabolite), accumulation is possible in elderly or hepatically impaired patients. Avoid in narrow-angle glaucoma. Abrupt discontinuation may precipitate withdrawal seizures.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Do not stop taking suddenly; taper under medical supervision to avoid withdrawal symptoms.,Avoid alcohol and other CNS depressants (e.g., opioids, sleep aids) as they increase sedation and respiratory depression risk.,May cause drowsiness, dizziness; avoid driving or operating machinery until effect is known.,Take with or without food. Do not crush or chew extended-release capsules.,Inform doctor if you have a history of substance abuse, liver disease, or glaucoma.,Use caution in elderly patients due to increased risk of falls and cognitive impairment.,Notify doctor immediately if you experience suicidal thoughts, unusual mood changes, or allergic reactions.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRANXENE vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
TRANXENE is a Benzodiazepine Anxiolytic that works by Benzodiazepine; enhances GABA-A receptor activity by binding to benzodiazepine site, increasing chloride ion influx and neuronal hyperpolarization.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRANXENE and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRANXENE is: 7.5 mg to 15 mg orally 2 to 4 times daily; maximum dose 90 mg/day.. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRANXENE and ACETAMINOPHEN AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRANXENE is classified as Category C. FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip/palate, when used during the first trimester. Second and third trimest. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.